KRAS and neoplasm: Immunogenic hotspot neoantigens should be prioritized, as they are theoretically likely to be clonal and stable.[3, 20] Previous studies covering different tumor types identified the T cell recognition of TP53 and KRAS hotspot epitopes, meanwhile the T cell receptor (TCR) library restricted to different HLA molecules against hotspots was created.[21] Based on the concept of library, our study also tested T cell activation upon encountering each TP53 mutation‐derived peptide, the immunogenicity of two peptides was validated.